Trials / Completed
CompletedNCT04948827
A First-in-Human Study of SBP-9330 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Camino Pharma, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBP-9330 | SBP-9330 oral capsules |
| DRUG | Placebo | Placebo oral capsules |
Timeline
- Start date
- 2021-07-20
- Primary completion
- 2023-03-06
- Completion
- 2023-03-06
- First posted
- 2021-07-02
- Last updated
- 2024-04-16
- Results posted
- 2024-04-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04948827. Inclusion in this directory is not an endorsement.